Purespring bottles up $105M series B for kidney gene therapy

Oct 9, 2024  · London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series …


Install CouponFollow Chrome Extension   CouponFollow Extension

$105
OFF

Purespring Bottles Up $105M Series B For Kidney Gene Therapy

6 days from now

Oct 9, 2024  · London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series …

fiercebiotech.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 – Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

purespringtx.com

$105
OFF

Gene Therapy Reduces Harmful Protein Levels In Mouse Kidneys

6 days from now

Oct 29, 2024  · Purespring bottles up $105M series B to bring kidney disease gene therapy to the clinic. In a mouse model of IgA nephropathy, mice given PS-002 had lower levels of …

fiercebiotech.com

$105
OFF

Purespring Nabs $105M To Take Gene Therapy Into The Clinic As …

6 days from now

Oct 9, 2024  · Purespring nabs $105M to take gene therapy into the clinic as IgAN field matures. Purespring Therapeutics has reeled in £80 million ($105 million) to test two gene therapies in …

packgene.com

$105
OFF

Purespring Bottles Up $105M Series B To Bring Kidney Disease Gene ...

6 days from now

October 9, 2024 ukbn News, Syndication Comments Off on Purespring bottles up $105M series B to bring kidney disease gene therapy to the clinic London-based biotech Purespring …

ukbn.org

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

globenewswire.com

$105
OFF

Purespring Secures $105m To Start Phase I/II Trial Of IgAN Gene …

6 days from now

P urespring Therapeutics has secured £80m ($105m) to kick start a Phase I/II trial of its experimental adeno-associated viral (AAV) gene therapy in a kidney disease. The London …

msn.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

biospace.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Oct 9, 2024  · Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy …

businessupturn.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

businessinsider.com

$105
OFF

Purespring Therapeutics Raised A $105M Series B Earlier This Month …

6 days from now

Oct 24, 2024  · Purespring Therapeutics raised a $105M series B earlier this month to advance AAV gene therapies for kidney diseases, including both monogenic and non-monogenic …

biotechtv.com

$105
OFF

Gene Therapy Reduces Harmful Protein Levels In Mouse Kidneys

6 days from now

Oct 29, 2024  · Purespring bottles up $105M series B to bring kidney disease gene therapy to the clinic In a mouse model of IgA nephropathy, mice given PS-002 had lower levels of …

fiercelifesciences.com

$104
OFF

Advancing Gene Therapy For Kidney Disease, Purespring Adds £80M

6 days from now

Oct. 9, 2024. By Nuala Moran. Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to take a gene therapy for a kidney …

bioworld.com

$105
OFF

Q&A With Fredrik Erlandsson - Purespring Therapeutics

6 days from now

Mar 6, 2024  · Purespring Therapeutics presents new preclinical data on novel gene therapy for IgA Nephropathy at ASN Kidney Week 2024. Purespring Therapeutics raises £80/$105 million …

purespringtx.com

$105
OFF

Purespring Nabs $105M To Take Gene Therapy Into The Clinic As …

6 days from now

Oct 9, 2024  · Purespring Therapeutics has reeled in £80 million ($105 million) to test two gene therapies in humans. The Sofinnova Partners-led Series B, disclosed Wednesday morning, …

endpts.com

FAQs about Purespring bottles up $105M series B for kidney gene therapy Coupon?

Will purespring bring kidney-tweaking gene therapy to the clinic?

London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series B cash. ...

Does purespring therapeutics have a kidney nephropathy program?

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the kidney. The Series B funding announced Wednesday was led by Sofinnova Partners and will support Purespring’s initiation of a Phase 1/2 study of its lead candidate for IgA nephropathy, or IgAN. ...

How much funding does purespring Therapeutics get for ps-002?

Purespring will use the $105m funding to advance its lead candidate PS-002 through the clinic. Credit: Pixel-Shot via Shutterstock. Purespring Therapeutics has secured £80m ($105m) to kick start a Phase I/II trial of its experimental adeno-associated viral (AAV) gene therapy in a kidney disease. ...

Why did purespring raise $105m?

The funds raised will allow us to bring our novel treatments to patients in the clinic.” "Purespring secures $105m to start Phase I/II trial of IgAN gene therapy " was originally created and published by Clinical Trials Arena, a GlobalData owned brand. ...

How does purespring treat kidney disease?

Purespring is the first company to successfully treat kidney disease models by directly targeting the podocyte, a specialised cell implicated in approximately 60% of renal diseases, through its proprietary adeno-associated viral (AAV) gene therapy platform. The Company currently has a pipeline of programmes in development. ...

Who is purespring Therapeutics?

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 million in a Series B financing. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension